Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PPM-204 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| PPM-204 | DRUG | - |
Inclusion Criteria: * Men or women, aged 18 to 55 years * Body mass index in the range of 18 to 30 kg/m2 * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG Exclusion Criteria: * History ...
PPM-204 is an investigational small molecule being developed for diabetes mellitus. It is a metabolic therapeutic that has been studied in early-stage clinical trials, though it is not yet approved and remains in clinical development.
PPM-204 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PPM-204 is in Phase 1 clinical development. It has completed two Phase 1 trials, and it is not yet approved by regulatory authorities. The drug remains investigational.
PPM-204 has completed two Phase 1 trials: NCT00447629, a study evaluating single doses on the electrical pathways of the heart in the United States, and NCT00448032, a study of multiple oral doses in healthy Japanese male subjects in Japan.
No alternative names for PPM-204 have been disclosed. It is identified solely by the code name PPM-204 in clinical trial records.